KRAS G12V mutation
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-KRAS-G12V |
|---|---|
| Type | Biomarker |
| Aliases | KRAS G12VМутація KRAS G12V |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-PANCREATIC-2025 |
Biomarker Facts
| Biomarker type | gene_mutation |
|---|---|
| Mutation details | {"exon": "2", "functional_impact": "activating", "gene": "KRAS", "hgvs_protein": "p.G12V", "variant_type": "missense"} |
| Measurement | MethodTumor-tissue NGS panel OR ctDNA NGS |
| Actionability lookup | {"gene": "KRAS", "variant": "G12V"} |
| Related biomarkers | BIO-KRAS-G12C BIO-KRAS-G12D BIO-RAS-MUTATION |
Notes
~25% of PDAC KRAS mutations, ~22% of CRC KRAS mutations. No FDA-approved G12V-selective therapy as of 2025. Adoptive T-cell therapy (TCR-T against G12V on HLA-A*11:01) — Memorial Sloan Kettering and others investigating. Like G12D, it confers resistance to anti-EGFR (cetuximab/panitumumab) in CRC.
Used By
Actionability
BMA-KRAS-G12V-CRC- KRAS G12V in mCRC — anti-EGFR contraindication marker, no targeted therapy. Standard chem...BMA-KRAS-G12V-ENDOMETRIAL- KRAS G12V in endometrial — POLE/MMR/p53 subtyping drives 1L.BMA-KRAS-G12V-NSCLC- KRAS G12V occurs in ~3–5% of NSCLC (less common than G12C ~13% and G12D ~5%). Unlike KRAS...BMA-KRAS-G12V-OVARIAN- KRAS G12V in low-grade serous / mucinous ovarian — no approved targeted therapy.BMA-KRAS-G12V-PDAC- KRAS G12V in PDAC — second-most common driver. No approved drug 2026; pan-KRAS inhibitors...